- Home
- BREA vs SABS Comparison
BREA vs SABS Comparison
Compare BREA & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- SABS
- Stock Information
- Founded
- BREA 2022
- SABS 2014
- Country
- BREA Ireland
- SABS United States
- Employees
- BREA N/A
- SABS N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- SABS Health Care
- Exchange
- BREA Nasdaq
- SABS Nasdaq
- Market Cap
- BREA 14.8M
- SABS 15.8M
- IPO Year
- BREA 2023
- SABS N/A
- Fundamental
- Price
- BREA $7.64
- SABS $2.46
- Analyst Decision
- BREA
- SABS Strong Buy
- Analyst Count
- BREA 0
- SABS 4
- Target Price
- BREA N/A
- SABS $9.50
- AVG Volume (30 Days)
- BREA 216.2K
- SABS 84.7K
- Earning Date
- BREA 01-01-0001
- SABS 11-05-2025
- Dividend Yield
- BREA N/A
- SABS N/A
- EPS Growth
- BREA N/A
- SABS N/A
- EPS
- BREA N/A
- SABS N/A
- Revenue
- BREA $2,988,009.00
- SABS $114,698.00
- Revenue This Year
- BREA N/A
- SABS N/A
- Revenue Next Year
- BREA N/A
- SABS N/A
- P/E Ratio
- BREA N/A
- SABS N/A
- Revenue Growth
- BREA 151.51
- SABS N/A
- 52 Week Low
- BREA $5.00
- SABS $1.00
- 52 Week High
- BREA $19.50
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- BREA 63.62
- SABS 63.65
- Support Level
- BREA $5.87
- SABS $2.05
- Resistance Level
- BREA $14.84
- SABS $2.18
- Average True Range (ATR)
- BREA 0.96
- SABS 0.12
- MACD
- BREA 0.19
- SABS 0.02
- Stochastic Oscillator
- BREA 21.14
- SABS 100.00
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.